{"drugs":["Combunox","Oxycodone\/Ibuprofen"],"mono":{"0":{"id":"928363-s-0","title":"Generic Names","mono":"Oxycodone\/Ibuprofen"},"1":{"id":"928363-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928363-s-1-4","title":"Adult Dosing","mono":"<ul><li>use lowest effective dose for shortest possible duration<\/li><li>after observing initial response, adjust dose and frequency to meet  individual patient's needs<\/li><li><b>Pain, acute (Moderate to Severe):<\/b> 1 tablet (oxycodone 5 mg\/ibuprofen 400 mg), MAX 4 tablets in 24-hr period (total for 24 hr, oxycodone 20 mg\/ibuprofen 1600 mg), with use not to exceed 7 days<\/li><\/ul>"},"1":{"id":"928363-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>oxycodone-ibuprofen has not been studied in patients under 14 year of age<\/li><li>use lowest effective dose for shortest possible duration<\/li><li>after observing initial response, adjust dose and frequency to meet  individual patient's needs<\/li><li><b>Pain, acute (Moderate to Severe):<\/b> (age 14 years and older) 1 tablet (oxycodone 5 mg\/ibuprofen 400 mg), MAX 4 tablets in 24-hr period (total for 24 hr, oxycodone 20 mg\/ibuprofen 1600 mg), with use not to exceed 7 days<\/li><\/ul>"},"3":{"id":"928363-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Pain, acute (Moderate to Severe)<br\/>"}}},"2":{"id":"928363-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Ibuprofen\/oxycodone hydrochloride is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.<br\/>"},"3":{"id":"928363-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928363-s-3-9","title":"Contraindications","mono":"<ul><li>treatment of perioperative pain in setting of coronary artery bypass graft (CABG) surgery; increased risk of myocardial infarction and stroke<\/li><li>angioedema, history; increased risk of anaphylactoid reaction<\/li><li>aspirin triad (bronchospasm in asthmatic patients with rhinitis, with or without nasal polyps following aspirin or non-steroidal antiinflammatory administration); increased risk of anaphylactoid reaction<\/li><li>asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal antiinflammatory agents; severe and sometimes fatal anaphylactoid reactions have been reported<\/li><li>bronchial asthma or hypercarbia, acute or severe; potential exacerbation<\/li><li>hypersensitivity to ibuprofen, oxycodone, other opioids, or any other component of the product<\/li><li>paralytic ileus, known or suspected<\/li><li>respiratory depression, significant<\/li><\/ul>"},{"id":"928363-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular disease, known or risk factors for; increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke; risk may increase with dose and duration of use<\/li><li>cardiovascular thrombotic events, including myocardial infarction and stroke, may occur; risk may increase with increased dose or duration of use<\/li><li>gastrointestinal adverse events (bleeding, ulceration, perforation of stomach or intestines) can occur at any time and without warning, increased risk in patients with a history of peptic ulcer disease or gastrointestinal bleeding, with concomitant use of oral corticosteroids, anticoagulants, or alcohol, with longer duration of therapy, and in smokers or debilitated patients; administer lowest effective dose for the shortest duration possible<\/li><li>acute abdominal conditions; diagnosis or clinical course may be obscured<\/li><li>acute alcoholism or delirium tremens; increased risk of respiratory depression, postural hypotension, and altered mental states<\/li><li>ambulatory patients; orthostatic hypotension may occur<\/li><li>anemia has been reported<\/li><li>aseptic meningitis with fever and coma has been reported rarely, increased risk in patients with lupus erythematosus or related connective tissue diseases<\/li><li>asthma; increased risk for anaphylactoid reactions<\/li><li>biliary tract disease, including acute pancreatitis; may cause spasm of the sphincter of Oddi and increase serum amylase level<\/li><li>chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, preexisting respiratory depression, hypoxia, or hypercapnia; apnea may occur with usual therapeutic doses<\/li><li>coagulation defects or anticoagulation therapy; may prolong bleeding time<\/li><li>circulatory shock; further reduction of cardiac output or blood pressure may occur<\/li><li>compromised blood pressure (eg, blood volume depletion or concomitant administration of phenothiazine or general anesthetics); potential for severe hypotension<\/li><li>drug dependence; risk of oxycodone abuse\/physical dependence<\/li><li>elderly patients; increased risk of fatal gastrointestinal events, respiratory depression, and renal injury<\/li><li>head injury, increased intracranial pressure, intracranial lesions; potential for exaggerated respiratory depression and elevation of cerebrospinal fluid pressure<\/li><li>heart failure; increased fluid retention and edema may occur<\/li><li>hepatic reactions, including increased liver function tests, and rarely jaundice, fatal fulminant hepatitis, liver necrosis, and hepatic failure, have been reported<\/li><li>hypertension, new or worsening of, may occur<\/li><li>hypothyroidism or Addison's disease; increased risk of respiratory depression, postural hypotension, and altered mental states<\/li><li>kyphoscoliosis associated with respiratory depression; increased risk of respiratory depression, postural hypotension, and altered mental states<\/li><li>pregnancy, avoid use especially at 30 weeks gestation and beyond; premature closure of the ductus arteriosis may occur<\/li><li>prostatic hypertrophy or urethral stricture; increased risk of respiratory depression, postural hypotension, and altered mental states<\/li><li>pulmonary disease or postoperative use; suppresses the cough reflex<\/li><li>renal disease, advanced<\/li><li>renal injury, including renal papillary necrosis, has been reported with long-term therapy; increased risk with renal impairment, heart failure, liver dysfunction, or concomitant use of diuretics and ACE inhibitors<\/li><li>respiratory depression, dose-related, may occur; increased risk with large initial doses in nontolerant patients or concomitant use of agents that cause respiratory depression<\/li><li>skin adverse events, serious; including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may occur without warning<\/li><li>toxic psychosis, seizures, CNS depression, or coma; increased risk of respiratory depression, postural hypotension, and altered mental states<\/li><\/ul>"},{"id":"928363-s-3-11","title":"Pregnancy Category","mono":"C (1st trimester), C (2nd trimester), D (3rd trimester) (FDA)<br\/>"},{"id":"928363-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk has been demonstrated.<br\/>"}]},"4":{"id":"928363-s-4","title":"Drug Interactions","sub":[{"id":"928363-s-4-13","title":"Contraindicated","mono":"<ul><li>Ketorolac (theoretical)<\/li><li>Naltrexone (probable)<\/li><\/ul>"},{"id":"928363-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Abiraterone (theoretical)<\/li><li>Acepromazine (theoretical)<\/li><li>Alfentanil (probable)<\/li><li>Alprazolam (theoretical)<\/li><li>Alvimopan (established)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Anileridine (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Aspirin (probable)<\/li><li>Atazanavir (theoretical)<\/li><li>Baclofen (probable)<\/li><li>Benperidol (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Brofaromine (theoretical)<\/li><li>Bromazepam (theoretical)<\/li><li>Buprenorphine (probable)<\/li><li>Buspirone (theoretical)<\/li><li>Butorphanol (probable)<\/li><li>Carisoprodol (probable)<\/li><li>Carphenazine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chlordiazepoxide (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorzoxazone (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clarithromycin (established)<\/li><li>Clobazam (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clopidogrel (probable)<\/li><li>Clorazepate (theoretical)<\/li><li>Clorgyline (theoretical)<\/li><li>Clovoxamine (probable)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Codeine (probable)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Darunavir (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Dexmedetomidine (theoretical)<\/li><li>Dezocine (probable)<\/li><li>Diacetylmorphine (theoretical)<\/li><li>Diazepam (theoretical)<\/li><li>Dichloralphenazone (theoretical)<\/li><li>Difenoxin (theoretical)<\/li><li>Dihydrocodeine (theoretical)<\/li><li>Diphenhydramine (theoretical)<\/li><li>Diphenoxylate (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxylamine (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enflurane (theoretical)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Estazolam (theoretical)<\/li><li>Eszopiclone (theoretical)<\/li><li>Ethchlorvynol (theoretical)<\/li><li>Ethopropazine (theoretical)<\/li><li>Ethylmorphine (theoretical)<\/li><li>Etomidate (theoretical)<\/li><li>Femoxetine (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Flunitrazepam (theoretical)<\/li><li>Fluoxetine (probable)<\/li><li>Fluphenazine (theoretical)<\/li><li>Flurazepam (theoretical)<\/li><li>Fluspirilene (theoretical)<\/li><li>Fluvoxamine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fospropofol (theoretical)<\/li><li>Furazolidone (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Halazepam (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Hexobarbital (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydromorphone (probable)<\/li><li>Hydroxyzine (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Iproniazid (theoretical)<\/li><li>Isocarboxazid (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Itraconazole (established)<\/li><li>Ketamine (theoretical)<\/li><li>Ketazolam (theoretical)<\/li><li>Ketobemidone (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lazabemide (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Levorphanol (probable)<\/li><li>Linezolid (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Loprazolam (theoretical)<\/li><li>Lorazepam (theoretical)<\/li><li>Lormetazepam (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Meclizine (theoretical)<\/li><li>Medazepam (theoretical)<\/li><li>Melperone (theoretical)<\/li><li>Meperidine (probable)<\/li><li>Meptazinol (probable)<\/li><li>Mesoridazine (theoretical)<\/li><li>Metaxalone (probable)<\/li><li>Methadone (theoretical)<\/li><li>Methdilazine (theoretical)<\/li><li>Methocarbamol (probable)<\/li><li>Methohexital (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Methotrimeprazine (theoretical)<\/li><li>Methylene Blue (theoretical)<\/li><li>Methylnaltrexone (established)<\/li><li>Midazolam (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Mitotane (theoretical)<\/li><li>Moclobemide (theoretical)<\/li><li>Molindone (theoretical)<\/li><li>Moricizine (theoretical)<\/li><li>Morphine (probable)<\/li><li>Morphine Sulfate Liposome (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nalbuphine (probable)<\/li><li>Nalmefene (established)<\/li><li>Nalorphine (established)<\/li><li>Naloxone (established)<\/li><li>Nefazodone (probable)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nialamide (theoretical)<\/li><li>Nicomorphine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nitisinone (theoretical)<\/li><li>Nitrazepam (theoretical)<\/li><li>Nitrous Oxide (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Opium (probable)<\/li><li>Orphenadrine (probable)<\/li><li>Oxazepam (theoretical)<\/li><li>Oxymorphone (probable)<\/li><li>Papaveretum (theoretical)<\/li><li>Paregoric (theoretical)<\/li><li>Pargyline (theoretical)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentazocine (probable)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Perazine (theoretical)<\/li><li>Periciazine (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenelzine (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperacetazine (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pipotiazine (theoretical)<\/li><li>Piritramide (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Prazepam (theoretical)<\/li><li>Procarbazine (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propofol (theoretical)<\/li><li>Propoxyphene (probable)<\/li><li>Protein C (theoretical)<\/li><li>Quazepam (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Ramelteon (theoretical)<\/li><li>Rasagiline (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Remifentanil (probable)<\/li><li>Remoxipride (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Ritonavir (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Samidorphan (established)<\/li><li>Saquinavir (theoretical)<\/li><li>Selegiline (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sertraline (probable)<\/li><li>Sibutramine (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Oxybate (theoretical)<\/li><li>Sufentanil (probable)<\/li><li>Sulpiride (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tapentadol (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (established)<\/li><li>Temazepam (theoretical)<\/li><li>Thiopropazate (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tilidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Tolonium Chloride (theoretical)<\/li><li>Toloxatone (theoretical)<\/li><li>Topiramate (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Tranylcypromine (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trifluperidol (theoretical)<\/li><li>Triflupromazine (theoretical)<\/li><li>Trimeprazine (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zaleplon (theoretical)<\/li><li>Zimeldine (probable)<\/li><li>Zolpidem (theoretical)<\/li><li>Zopiclone (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"928363-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amikacin (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desipramine (probable)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Fluconazole (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Fosphenytoin (probable)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Miconazole (established)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perampanel (probable)<\/li><li>Perindopril (established)<\/li><li>Phenytoin (probable)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Rifampin (established)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>St John's Wort (established)<\/li><li>Tacrine (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Voriconazole (established)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},"5":{"id":"928363-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Vasodilatation (3%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (8.8% to 25.4%), Vomiting (4.5% to 5.3%)<\/li><li><b>Hepatic:<\/b>Increased liver function test (up to 15%)<\/li><li><b>Neurologic:<\/b>Dizziness (5.1% to 19.2%), Headache (10.2%), Somnolence (7.3% to 17.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction, Tachycardia (less than 1%), Thrombotic tendency observations<\/li><li><b>Dermatologic:<\/b>Erythroderma, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage, Gastrointestinal perforation, Gastrointestinal ulcer, Inflammatory disorder of digestive tract<\/li><li><b>Hepatic:<\/b>Hepatitis, Jaundice, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Renal:<\/b>Acute renal failure<\/li><li><b>Respiratory:<\/b>Respiratory depression<\/li><\/ul>"},"6":{"id":"928363-s-6","title":"Drug Name Info","sub":{"0":{"id":"928363-s-6-17","title":"US Trade Names","mono":"Combunox<br\/>"},"2":{"id":"928363-s-6-19","title":"Class","mono":"<ul><li>NSAID<\/li><li>Opioid<\/li><li>Opioid\/NSAID Combination<\/li><li>Propionic Acid (class)<\/li><\/ul>"},"3":{"id":"928363-s-6-20","title":"Regulatory Status","mono":"Schedule II<br\/>"},"4":{"id":"928363-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"928363-s-7","title":"Mechanism Of Action","mono":"<ul><li>Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) with both antipyretic and analgesic activities. Its mode of action is related to its suppression of cyclooxygenase activity and prostaglandin synthesis.<\/li><li>Oxycodone hydrochloride is a semisynthetic opioid analgesic used in the short treatment of acute, moderate to severe pain. Its mode of action is unknown, but is postulated to be associated to its binding to mu-opiate receptors in the central nervous system. It may also produce sedation and respiratory depression.<\/li><\/ul>"},"8":{"id":"928363-s-8","title":"Pharmacokinetics","sub":[{"id":"928363-s-8-23","title":"Absorption","mono":"<ul><li>Ibuprofen: time to peak concentration, 1.6 h to 3.1 h<\/li><li>Oxycodone HCl: time to peak concentration, 1.3 h to 2.1 h<\/li><li>Ibuprofen, Effect of food: none<\/li><li>Oxycodone HCl, Effect of food: bioavailability increased by 25%<\/li><\/ul>"},{"id":"928363-s-8-24","title":"Distribution","mono":"<ul><li>Ibuprofen, Protein binding: 99%<\/li><li>Oxycodone HCl, Protein binding: approximately 45%<\/li><\/ul>"},{"id":"928363-s-8-25","title":"Metabolism","mono":"<ul><li>Ibuprofen, metabolites: (+)-2-4'-(2-hydroxy-2-methyl-propyl) phenyl propionic acid and (+)-2-4'-(carboxypropyl) phenyl propionic acid<\/li><li>Oxycodone HCl-Hepatic; P450 CYP2D6, N-demethylation and O-demethylation, 6-ketoreduction and glucuronidation<\/li><li>Metabolites: noroxycodone and oxymorphone<\/li><\/ul>"},{"id":"928363-s-8-26","title":"Excretion","mono":"<ul><li>Ibuprofen, Renal: less than 0.2% unchanged<\/li><li>Oxycodone HCl: approximately 4% unchanged<\/li><\/ul>"},{"id":"928363-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Ibuprofen: 1.8 h to 2.6 h<\/li><li>Oxycodone: 3.1 h to 3.7 h<\/li><\/ul>"}]},"10":{"id":"928363-s-10","title":"Monitoring","mono":"<ul><li>pain reduction is indicative of efficacy<\/li><li>CBC and chemistry profile,  periodically<\/li><li>patients with a coagulation disorder<\/li><li>renal function; in patients with advanced kidney disease<\/li><\/ul>"},"11":{"id":"928363-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Oral Tablet: (Ibuprofen - Oxycodone Hydrochloride) 400 MG-5 MG<br\/>"},"12":{"id":"928363-s-12","title":"Toxicology","sub":[{"id":"928363-s-12-31","title":"Clinical Effects","mono":"<ul><li><b>IBUPROFEN <\/b><br\/>USES: Ibuprofen is used for fever and pain control and for the treatment of several rheumatologic conditions. PHARMACOLOGY: Ibuprofen inhibits the cyclooxygenase enzyme, leading to decreased prostaglandin production and decreased pain and inflammation. TOXICOLOGY: Gastrointestinal (GI) symptoms are due to both local irritant effects and the inhibition of prostaglandins (PG), which are responsible in part for maintaining the GI mucosal barrier. Inhibition of thromboxane A2 production in platelets prolongs bleeding time and contributes to gastrointestinal bleeding. Inhibition of PGI2 and PGE2, which have vasodilatory and natriuretic activity in the kidney, can be linked to sodium and water retention and occasional acute renal failure. EPIDEMIOLOGY: Overdose is common; however, severe toxicity is very rare. MILD TO MODERATE TOXICITY: In general, patients are asymptomatic or have mild GI upset (ie, nausea, vomiting, abdominal pain). Mild CNS depression (drowsiness, lethargy) and headache are common (incidence up to 30%). Nystagmus, diplopia, headache, tinnitus, and transient deafness may also occur following overdose. SEVERE TOXICITY: With massive overdose, seizure, coma, acute renal failure, and, very rarely, cardiopulmonary arrest may occur. Upper GI bleeding may occur after acute or chronic ingestion. Elevated liver enzymes, hypoprothrombinemia, metabolic acidosis, hypokalemia, hypophosphatemia, hyponatremia, and hyperkalemia (associated with renal failure), hypotension, bradycardia, tachycardia, atrial fibrillation, dyspnea, aspiration pneumonia, rhabdomyolysis, and disseminated intravascular coagulation have also been observed in overdose. Transient episodes of apnea have been reported in young children following large ingestions. Acute pancreatitis has been reported. ONSET: Symptoms typically occur within 4 to 6 hours of ingestion. ADVERSE EFFECTS: Gastrointestinal distress, nausea, and epigastric pain are the most common findings; upper GI bleeding may occur after acute or chronic ingestion. Angioedema, hives, itching, rash, and swelling have also been reported with therapeutic use. Fluid retention, interstitial nephritis, nephritic syndrome, and acute renal failure can develop. Hematologic effects include agranulocytosis, aplastic anemia, and thrombocytopenia. Headache, asthma exacerbation, aseptic meningitis, delirium, and anaphylactoid reactions have also been reported.<br\/><\/li><li><b>OXYCODONE  <\/b><br\/>USES: Oxycodone is primarily used for the treatment of pain. Oxycodone is commonly abused for euphoric effects by multiple routes (i.e., injection, insufflation, smoking, ingestion). EPIDEMIOLOGY: Overdose is common, particularly in patients with chronic opioid abuse, and may be life threatening. PHARMACOLOGY: Oxycodone binds at the opiate receptors. TOXICOLOGY: Therapeutic and toxic effects are mediated by different opioid receptors. Mu 1: Supraspinal and peripheral analgesia, sedation, and euphoria. Mu 2: Spinal analgesia, respiratory depression, physical dependence, GI dysmotility, bradycardia and pruritus. Kappa 1: Spinal analgesia and miosis. Kappa 2: Dysphoria and psychotomimesis. Kappa 3: Supraspinal analgesia. Chronic opioid users develop tolerance to the analgesic and euphoric effects, but not to the respiratory depression effects. OVERDOSE: MILD TO MODERATE POISONING: Euphoria, drowsiness, constipation, nausea, vomiting and pinpoint pupils. Mild bradycardia or hypotension may be present. SEVERE POISONING: Respiratory depression leading to apnea, hypoxia, coma, bradycardia, prolonged QT, or acute lung injury. Rarely, seizures may develop from hypoxia. Death may result from any of these complications.<br\/><\/li><\/ul>"},{"id":"928363-s-12-32","title":"Treatment","mono":"<ul><li><b>IBUPROFEN <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Most ibuprofen toxicity resolves with supportive care. Otherwise healthy patients with a history of ibuprofen poisoning generally require only supportive care and fluid and electrolyte replacement. MANAGEMENT OF SEVERE TOXICITY: Maintain an open airway and support ventilation. Treat seizures with benzodiazepines, hypotension with fluids and adrenergic vasopressors, and coma with intubation. Monitor ECG and arterial blood gases in patients with severe toxicity.<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal can be given to patients with significant overdose (more than 200 mg\/kg) who are alert and can protect their airway. HOSPITAL: Activated charcoal binds ibuprofen and should be administered after significant overdose (more than 200 mg\/kg). Gastric lavage is rarely, if ever, indicated, as this drug is absorbed rapidly and severe toxicity is exceedingly rare.<\/li><li>Airway management: Endotracheal intubation should be considered for patients who present with CNS depression (rare).<\/li><li>Antidote: None<\/li><li>Hypotensive episode: IV 0.9% NaCl 10 to 20 ml\/kg, dopamine, norepinephrine.<\/li><li>Anaphylaxis: Mild: antihistamines; Severe: airway management, epinephrine, ECG monitoring, fluids.<\/li><li>Acidosis: Administer sodium bicarbonate 1 to 2 mEq\/kg intravenously for severe acidosis (pH less than 7.1). Monitor arterial pH and blood gases to guide bicarbonate therapy.<\/li><li>Monitoring of patient: Serum ibuprofen levels are not available in most hospital laboratories and are not necessary for clinical management. Measure serum electrolytes, creatinine and BUN. If significant CNS or respiratory toxicity is present, assess acid-base status. Obtain serum acetaminophen level. Monitor for gastrointestinal bleeding.<\/li><li>Enhanced elimination procedure: Ibuprofen is highly protein-bound; hemodialysis is unlikely to be effective.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic children with inadvertent ingestions of less than 200 mg\/kg can be managed at home with milk or water dilution and observation. OBSERVATION CRITERIA: Symptomatic children, adults with deliberate ingestion, and children ingesting more than 200 mg\/kg should be referred to a health care facility for observation and treatment. Most patients who have ingested significant amounts of ibuprofen will manifest symptoms within 4 to 6 hours. ADMISSION CRITERIA: Patients who develop CNS depression, hypotension, acidosis, or gastrointestinal bleeding should be admitted.<\/li><\/ul><\/li><li><b>OXYCODONE  <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients may only need observation. MANAGEMENT OF SEVERE TOXICITY: Administer oxygen and assist ventilation for respiratory depression. Naloxone is the antidote indicated for severe toxicity (respiratory or CNS depression). Orotracheal intubation for airway protection should be performed early in cases of obtundation and\/or respiratory depression that do not respond to naloxone, or in patients who develop severe acute lung injury.<\/li><li>Decontamination: PREHOSPITAL: GI decontamination is generally not indicated because of the risk of CNS depression and aspiration. HOSPITAL: Consider activated charcoal if a patient presents soon after an ingestion and is not manifesting signs and symptoms of toxicity. Activated charcoal is generally not recommended in patients with significant signs of toxicity because of the risk of aspiration. Gastric lavage is not recommended as patients usually do well with supportive care.<\/li><li>Airway management: Administer oxygen and assist ventilation for respiratory depression. Orotracheal intubation for airway protection should be performed early in cases of obtundation and\/or respiratory depression that do not respond to naloxone, or in patients who develop severe acute lung injury.<\/li><li>Antidote: NALOXONE, an opioid antagonist, is the specific antidote. Naloxone can be given intravascularly, intramuscularly, subcutaneously, intranasally or endotracheally. The usual dose is 0.4 to 2.0 mg IV. In patients with suspected opioid dependence, incremental doses of 0.2 mg IV should be administered, titrated to reversal of respiratory depression and coma, to avoid precipitating acute opioid withdrawal. Doses may be repeated every 2 to 3 minutes up to 20 mg. Very high doses are rarely needed. A CONTINUOUS infusion is likely to be necessary after a controlled-release oxycodone ingestion. A suggested starting rate is two-thirds of the dose effective for initial reversal that is administered each hour; titrate as needed. DURATION of effect is usually 1 to 2 hours. Oxycodone has a much longer duration of effect, so it is necessary to observe the patient at least 4 hours after the last dose of naloxone to ensure that the patient does not have recurrent symptoms of toxicity. Naloxone can precipitate withdrawal in an opioid-dependent patients, which is usually not life-threatening; however it can be extremely uncomfortable for the patient.<\/li><li>Seizure: Seizures are rare, but may be a result of hypoxia. Treatment includes ensuring adequate oxygenation, and administering intravenous benzodiazepines; propofol or barbiturates may be indicated, if seizures persist.<\/li><li>Acute lung injury: Acute lung injury can develop in a small proportion of patients after an acute opioid overdose. The pathophysiology is unclear. Patients should be observed for 4 to 6 hours after overdose to evaluate for hypoxia and\/or the development of acute lung injury. Continuous oxygen therapy, pulse oximetry, PEEP and mechanical ventilation may be necessary.<\/li><li>Hypotensive episode: Hypotension is often reversed by naloxone. Initially treat with a saline bolus, if patient can tolerate a fluid load; then add adrenergic vasopressors to raise mean arterial pressure if hypotension persists.<\/li><li>Monitoring of patient: Monitor vital signs frequently, pulse oximetry, and continuous cardiac monitoring. Monitor for CNS and respiratory depression. Oxycodone plasma levels are not clinically useful or readily available. Urine toxicology screens may confirm exposure, but are rarely useful in guiding therapy. Obtain a baseline acetaminophen and salicylate levels in a patient with a suspected overdose, as oxycodone is often present in combination products. Routine lab work is usually not indicated, unless it is helpful to rule out other causes or if the diagnosis of opioid toxicity is uncertain. Obtain a chest x-ray for persistent hypoxia. Consider a head CT and\/or lumbar puncture to rule out an intracranial mass, bleeding or infection, if the diagnosis is uncertain.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value because of the large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Respiratory depression may occur at doses just above a therapeutic dose. Children should be evaluated in the hospital and observed as they are generally opioid-naive and may develop respiratory depression. Adults should be evaluated by a health care professional if they have received a higher than recommended (therapeutic) dose, especially if opioid-naive. OBSERVATION CRITERIA:  Patients with deliberate ingestions, adults with symptoms or ingestions of more than the therapeutic dose, or a pediatric ingestion should be sent to a healthcare facility for evaluation and treatment. IMMEDIATE RELEASE: Monitor for at least 4 to 6 hours. Patients who are treated with naloxone should be observed for 4 to 6 hours after the last dose, for recurrent CNS depression or acute lung injury. CONTROLLED RELEASE: Patients ingesting controlled-release preparations should be observed for at least 12 hours and admitted if symptoms develop (Tmax is 4.2 to 5.1 hours at a therapeutic dose and the drug can continue to be released from the controlled release preparation for 24 to 48 hours; effects may be delayed and prolonged). ADMISSION CRITERIA: IMMEDIATE RELEASE: Those with significant, persistent central nervous system depression should be admitted to the hospital. A patient needing more than 2 doses of naloxone should be admitted as a controlled-release formulation has likely been taken; additional doses may be needed. Patients with coma, seizures, dysrhythmias, delirium, and those needing a naloxone infusion or who are intubated should be admitted to an intensive care setting. CONTROLLED RELEASE: Patients with even mild to moderate opioid effects, and those who require naloxone after ingestion of a controlled-release formulation should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear. Refer patients for substance abuse counseling if indicated.<\/li><\/ul><\/li><\/ul>"},{"id":"928363-s-12-33","title":"Range of Toxicity","mono":"<ul><li><b>IBUPROFEN<\/b><br\/>TOXICITY: Ingestions of less than 200 mg\/kg rarely cause significant toxicity; ingestions of greater than 400 mg\/kg may result in serious effects. ADULTS: Overdoses of up to 48 g have been well tolerated by healthy adults. An adult died following an overdose of 105 g of sustained-release ibuprofen. THERAPEUTIC DOSE: ADULT: OTC: 200 mg orally every 4 to 6 hours as needed; PRESCRIPTION: 400 to 800 mg orally every 6 to 8 hours as needed. PEDIATRIC: OTC: 5 to 10 mg\/kg.<br\/><\/li><li><b>OXYCODONE<\/b><br\/>A toxic dose can vary widely depending on the opioid tolerance of the exposed individual. Doses of more than 40 mg can cause fatal respiratory depression in non-tolerant adults. Abusing controlled release products (eg, crushing and snorting, injecting) causes rapid absorption, high peak concentrations, and increased toxicity.<br\/><\/li><\/ul>"}]},"13":{"id":"928363-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness or somnolence.<\/li><li>Instruct patient to rise slowly from a sitting\/supine position, as drug may cause orthostatic hypotension.<\/li><li>This drug may cause sweating, excessive upper gastrointestinal gas, nausea, vomiting, headache, lethargy, scaling eczema, or bronchospasm.<\/li><li>Advise patient to immediately report signs\/symptoms of cardiovascular thrombotic events, myocardial infarction, or stroke.<\/li><li>Counsel patient, especially if elderly or debilitated, to report signs\/symptoms of gastrointestinal hemorrhage, ulceration, or perforation.<\/li><li>Tell patient to report signs\/symptoms of respiratory depression, renal\/hepatic dysfunction, Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering), or toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li>Advise patient to report signs\/symptoms of fluid retention, edema, or weight gain.<\/li><li>Instruct patient to avoid taking other CNS depressants, as concurrent use may have additive effects, including severe hypotension or respiratory depression.<\/li><li>Patient should not take other NSAIDs with this drug, unless approved by healthcare professional.<\/li><li>Tell patient to avoid drinking alcohol and smoking, as this may increase risk for gastrointestinal bleeding.<\/li><\/ul>"}}}